Myocor® is a clinical stage medical device company committed to developing and commercializing innovative, therapeutic products to treat mitral valve insufficiency and heart failure. The companies proprietarty Shape Change Therapy combined with its novel technologies provides less invasive approaches to treating disease states stemming from geometrically remodeled hearts.
The company has completed development, pre clinical studies, and early clinical evaluation on new technologies for the treatment of mitral regurgitation and heart failure. Myocor’s current focus is on the initiation and execution of a North American based clinical study evaluating the Coapsys™ System*.
The Coapsys is an innovative device and therapy designed to treat mild to severe mitral valve insufficiency with a less invasive, off pump, closed heart procedure. The Coapsys therapy was developed to treat mitral regurgitation, improve cardiac function, and better patient outcomes.